Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 253

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 253
---
 deferred revenue. The Company’s accounts payable and accrued expense balances increased in each year. Financing Activities Net cash provided by financing activities was $300,000 for the year ended May 31, 2025, representing proceeds from a founder loan. Proceeds from founder loans amounted to $200,000 in the year ended May 31, 2024. Funding Requirements DiamiR has not completed development of any of its product candidates. DiamiR expects to continue to incur operating losses in the foreseeable future. Subject to receiving additional financing, it anticipates that its expenses will increase substantially due to continued development of CogniMIR ®,, increased development activities for pipeline projects and planned commercialization efforts. DiamiR expects that its existing cash and cash equivalents, and anticipated interest income, will not enable it to complete its development of CogniMIR ®. DiamiR’s forecast of the period of time through which its financial resources will be adequate to support its operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in the section entitled “Risk Factors” and elsewhere in this proxy statement/prospectus. DiamiR has based this estimate on assumptions that may prove to be wrong, and it could utilize its available capital resources sooner than currently expected. DiamiR’s future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:

| ● | the initiation, progress, timing, costs, and results of clinical 
 validation for CogniMIR®                                         |

| ● | the terms and timing of any future collaboration, licensing, 
 or other arrangements that DiamiR may establish;             |

| ● | the outcome, timing, and cost of meeting regulatory requirements; |

| ● | the cost of obtaining, maintaining, defending, and enforcing 
 intellectual property rights, including patent rights;       |

| ● | the effect of competing technological and market developments; |

| ● | market acceptance of CogniMIR® if DiamiR meets         
 regulatory requirements for its commercialization; and |

| ● | the extent to which DiamiR acquires, licenses, or invests 
 in businesses, products or technologies.                  |

150 Until DiamiR can generate a sufficient amount of revenue from CogniMIR ®and related services and products, if ever, DiamiR expects to finance future cash needs through public or private equity offerings, debt financings or